Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05573386 · ClinicalTrials.gov registry record
Comparison of Quality and Quantity of M-PRP Cellular Content Filgrastim vs. Pegfilgrastim
A clinical trial, sponsored by Andrews Research & Education Foundation.
- Completed
- Registry status
- 15
- Enrollment target
NCT05573386: Completed study, sponsored by Andrews Research & Education Foundation.
NCT05573386 is a clinical trial that has completed, run by Andrews Research & Education Foundation. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05573386 has completed, sponsored by Andrews Research & Education Foundation.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
Study Summary
The goal of this prospective, observational study is to compare the quality and quantity of the cellular content of platelet-rich plasma harvested after administering one of two cell-stimulating proteins, filgrastim and pegfilgrastim. The main question it aims to answer is: • Will participants have a similar cellular content when comparing a 4-day filgrastim treatment to a one-day pegfilgrastim treatment? Participants will have the following intervention administered: * 130mL of blood will be drawn on the first visit after consent and in followup visits after administering treatment (4 days for filgrastim, 7 days for pegfilgrastim) * Half of all participants will receive filgrastim first, followed by pegfilgrastim 8 weeks after filgrastim treatment concludes. The other half will receive the treatments in reverse order Researchers will compare the quality and quantity of cell content after each treatment administration as well as comparing differences in data dependent on which order treatment was given.
Primary Outcome
Machine utilizing centrifugation and optics to precisely separate cell types using buffy coat method. . All cells have a density range and non-uniformly after centrifugation. Arthrex Angel system has the unique ability to isolate specific cells using inherent properties of cells that absorb differing wavelengths of light. The settings on the system can be controlled to adjust the proportion of cells versus plasma. Increasing the setting from 7% to 15%, the Angel system isolates more cells from a
Interventions
- DRUG Filgrastim
- DRUG Pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-08-09 |
| Est. Completion | 2023-10-05 |
What the finished NCT05573386 record still lists
NCT05573386 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Filgrastim is the first listed.
NCT05573386 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05573386 about?
NCT05573386 is a clinical study titled "Comparison of Quality and Quantity of M-PRP Cellular Content Filgrastim vs. Pegfilgrastim". The goal of this prospective, observational study is to compare the quality and quantity of the cellular content of platelet-rich plasma harvested after administering one of two cell-stimulating proteins, filgrastim and pegfilgrastim. The main question it aims to answer is: • Will participants have...
What is the current status of trial NCT05573386?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2021-08-09. Estimated completion is 2023-10-05.
What interventions are being tested in trial NCT05573386?
The interventions under investigation include: Filgrastim (DRUG), Pegfilgrastim (DRUG).
Who is sponsoring clinical trial NCT05573386?
This trial is sponsored by Andrews Research & Education Foundation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI